*3.1.7 The use of pulmonary vasodilator therapy*

The use of pulmonary vasodilator therapy with INO or epoprostenol (Flolan) is indicated for: (i) hypoxemia during single-lung ventilation, (ii) refractory hypoxemia in severe primary graft dysfunction (PGD), (iii) to prevent/mitigate exacerbations in PHTN and subsequent cardiorespiratory perturbations during induction and pulmonary artery clamping and thus potentially avoiding the institution of CPB [14].
